Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab ... available in both subcutaneous injection and intravenous infusion.

On March 12, 2025, Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab ... for subcutaneous injection or intravenous ...

Cigna's (NYSE:CI) pharmacy benefit manager, Evernorth Health Services, announced on Thursday plans to launch a biosimilar to Johnson & Johnson's (NYSE:JNJ) blockbuster arthritis therapy Stelara ...

A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent expiry date. The complaint ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...